Fig. 7

Knockdown of miR-9-5p impaired the cardioprotection afforded by iPSC-MSC-EXOs against DIC. A Schematic chart showing the introduction of DIC model and administration of iPSC-MSC-EXOs or miR-9-5p^KD-iPSC-MSC-EXOs. B Representative echocardiographic images were captured on day 35 after DOX treatment in mice that received iPSC-MSC-EXOs or miR-9-5p^KD-iPSC-MSC-EXOs. C The LVEF and LVFS were analyzed at 35 days in DIC mice that received iPSC-MSC-EXO or miR-9-5p^KD-iPSC-MSC-EXO treatment. D Representative images of Sirius red staining of heart sections from DIC mice that received iPSC-MSC-EXO or miR-9-5p^KD-iPSC-MSC-EXO treatment. E Quantitative analysis of cardiac fibrosis in DIC mice that received iPSC-MSC-EXO or miR-9-5p^KD-iPSC-MSC-EXO treatment. F Representative images of Troponin and p21 double staining in the heart of DIC mice that received iPSC-MSC-EXO or miR-9-5p^KD-iPSC-MSC-EXO treatment. G Quantitative measurement of Troponin⁺/p21⁺ double-positive cells in the heart of DIC mice that received iPSC-MSC-EXO or miR-9-5p^KD-iPSC-MSC-EXO treatment. H Representative TEM images showing the mitochondria in the heart of DIC mice that received iPSC-MSC-EXO or miR-9-5p^KD-iPSC-MSC-EXO treatment. I Quantitative measurement of mitochondrial fragmentation in the heart of DIC mice that received iPSC-MSC-EXO or miR-9-5p^KD-iPSC-MSC-EXO treatment. Data are expressed as mean ± SD. n = 6 mice for each group, ***p < 0.001